Overview

Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Status:
Unknown status

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of Chidamide with EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Phase:

Phase 2

Details

Lead Sponsor:

Yuankai Shi